RESEARCH ARTICLE

The characteristics of pain and dysesthesia in patients with diabetic polyneuropathy

Sandra Sif Gylfadottir1,2*, Mustapha Itани3, Alexander Gramm Kristensen4, Pall Karlsson1,5, Thomas Kreigård3, David L. Bennett6, Hatice Tankisi4, Niels Trolle Andersen7, Troels Staehelin Jensen1,2, Søren Hein Sindrup3, Nanna Brix Finnerup1,2

1 Danish Pain Research Center, Department of Clinical Medicine, Aarhus University, Aarhus, Denmark, 2 Department of Neurology, Aarhus University Hospital, Aarhus, Denmark, 3 Department of Neurology, Odense University Hospital, Odense, Denmark, 4 Department of Clinical Neurophysiology, Aarhus University Hospital, Aarhus, Denmark, 5 Core Center for Molecular Morphology, Section for Stereology and Microscopy, Aarhus University, Denmark, 6 Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, United Kingdom, 7 Biostatistics, Department of Public Health, Aarhus University, Aarhus, Denmark

* sifgyl@clin.au.dk

Abstract

Introduction/aims

Patients with diabetic polyneuropathy (DPN) may experience paresthesia, dysesthesia, and pain. We aimed to characterize the predictors, symptoms, somatosensory profile, neuropathy severity, and impact of painful DPN and dysesthetic DPN.

Methods

This study was a cross-sectional study of type 2 diabetes patients with confirmed DPN, diagnosed using widely accepted methods including a clinical examination, skin biopsy, and nerve conduction studies.

Findings

Of 126 patients with confirmed DPN, 52 had DPN without pain or dysesthesia, 21 had dysesthetic DPN, and 53 painful DPN. Patients with painful DPN were less physically active and suffered from more pain elsewhere than in the feet compared to patients with DPN without pain. Patients with painful DPN had the largest loss of small and large sensory fiber function, and there was a gradient of larger spatial distribution of sensory loss from DPN without dysesthesia/pain to dysesthetic DPN and to painful DPN. This could indicate that patients with dysesthesia had more severe neuropathy than patients without dysesthesia but less than patients with painful DPN. Patients with dysesthetic and painful DPN had higher symptom scores for depression and fatigue than those without dysesthesia/pain with no difference between dysesthetic and painful DPN.
Pain and dysesthesia in diabetic polyneuropathy

Conclusions
There was a gradient of increasing sensory loss from DPN without dysesthesia/pain to dyesthetic DPN and to painful DPN. Pain and dysesthesia are common in DPN and both interfere with daily life. It is therefore important to consider dysesthesia when diagnosing and treating patients with neuropathy.

Introduction
Diabetic polyneuropathy (DPN) is one of the most common complications to type 2 diabetes, affecting up to 50% of the patients [1]. Of those, around 50% have painful DPN [2, 3], and with a high global prevalence of type 2 diabetes [3, 4], it represents one of the major causes of neuropathic pain.

Little is known about the risk factors for developing neuropathic pain in those with DPN [2, 3, 5]; however, studies consistently point to an increasing severity of chronic sensory polyneuropathy as a risk factor for neuropathic pain in patients with longstanding diabetes [5–8].

Patients with lesions or disease of the somatosensory nerve system may experience spontaneous or evoked sensations ranging from paresthesia (an abnormal sensation) over dysesthesia (an unpleasant abnormal sensation, whether spontaneous or evoked) to pain, which is defined as an unpleasant sensory and emotional experiences associated with, or resembling that associated with, actual or potential tissue damage [9, 10]. These symptoms are well-characterized in central neurological disorders. Patients may report both pain and dysesthesia, but a large proportion of patients with stroke or spinal cord injury report only dysesthesia, either spontaneous dysesthesia and/or dysesthesia evoked by e.g. cold and light touch [11–15]. Dysesthesia can be distressing whether painful or not [16] and should be considered in the assessment of patients as they may not report dysesthesia if only asked about pain. In stroke and spinal cord injury, early evoked pain or dysesthesia to light touch, cold or pinprick have been found to predict the later development of central neuropathic pain, with more patients reporting evoked dysesthesia (unpleasantness) than pain [17, 18], emphasizing the importance of assessing dysesthesia. While pain and sensory loss are often addressed in the context of DPN, no attention has been given to dysesthesia, and we do not know if pain and dysesthesia share important features with respect to predictors, mechanisms, and impact. We have therefore separated pain and dysesthesia in the present study.

In this study, we hypothesized that patients with dysesthesia had more severe neuropathy than patients without dysesthesia but less than patients with neuropathic pain. We also aimed to describe the predictors, symptoms, somatosensory profile and impact of dyesthetic and painful DPN.

Materials and methods
Study design and patients
Patients with DPN participating in a cross-sectional detailed phenotyping study of 389 patients with type 2 diabetes performed from October 2016 to October 2018 [19] were included in this study. The patients had participated in a questionnaire survey of 5,514 type 2 diabetes patients from a large prospective cohort study: the Danish Centre for Strategic Research in Type 2 diabetes (DD2) [20, 21]. Briefly, in this study we included all 126 patients with confirmed DPN diagnosed according to the Toronto Diabetic Neuropathy Expert Group criteria [22] and all
patients had abnormal nerve conduction studies (NCS) or/and intra epidermal nerve fiber density (IENFD).

We excluded patients with other causes of polyneuropathy and other neurological or pain disorders that could not be distinguished from the symptoms of DPN. We also included 97 controls without diabetes, severe illness or chronic pain of similar age and sex as the patients. They were recruited by flyers and within the social circle of the patient i.e. spouses and friends. The characteristics of the control group without diabetes is described previously [19]. Data from the control group was only used for comparison in bedside sensory mapping.

**Interview and neurological examination**

The patients came in for a 1-day visit that consisted of a structured interview, a clinical examination, and a self-administered questionnaire as described previously [19]. The interview focused on symptoms of neuropathy (duration, localization, and type of symptoms). Patients were also asked about pain medicine and comorbidities, including diseases that cause polyneuropathy and pain. We measured weight, height, blood pressure, and took blood samples for glycated hemoglobin (HbA1c), cholesterol, and triglycerides on the same day as the examination.

The bedside neurological examination was performed in a quiet environment and consisted of sensory mapping of lower extremities: light brush stroking (SENSELab Brush-05; Somedic AB, Hörby, Sweden), pinprick (Owen Mumford Neuropen with sterile neurotips and Semmes-Weinstein monofilament no 5.88 (bending force 75.9 g/745 mN), Stoeleting, Wood Dale, IL, USA) and cold (20˚C) and warm (40˚C) thermal rolls (Somedic AB, Hörby, Sweden). All modalities were tested in a control area with normal sensation (upper thigh or chest) and then examined starting in the toes and moving proximally. Patients were asked if the stimulus was the same or similar to the control stimulus, less intense, more intense or painful. If it was painful patients rated the pain on the Numeric Rating Scale (NRS). We started the examination systemically on the right side. We also assessed reflexes and muscle strength. To ensure consistency between the 2 investigators, we made a detailed description of the examination, trained together, and tested regularly for agreement.

**Questionnaire**

All patients filled in a questionnaire on the day of the clinical examination. The questionnaire consisted of questions about occupational status, educational level, smoking and alcohol consumption (> 7/14 units of alcohol per week (women/men), which is the maximum safe amount recommended by the Danish Health Authority). Additionally, the patients reported how often on average per week they were physically active.

The patients were asked to rate their overall quality of life (QoL) on the 0–10 NRS, where 10 indicated the best QoL possible and 0 the worst during the last 7 days [23]. We asked about sleep disturbance, symptoms of depression and anxiety as well as pain interference with daily life (e.g., with social, recreational and physical activities) using the Patient-Reported Outcome Measurement Information System (PROMIS®) 4a short form v1.0. The scores were converted into PROMIS T scores, which are standardized relative to an American/US reference population, and to categories of impairment ranging from normal through mild impairment and moderate impairment to severe impairment [24, 25].

Patients with dysesthesia and pain filled in the Neuropathic Pain Symptom Inventory (NPSI), a questionnaire designed to evaluate the symptoms of neuropathic pain, their presence, character, and intensity [26]. Although not developed or validated to assess dyesthesia, patients with dysesthesia were asked to characterize their dyesthesia the using NPSI with and the term “pain” in the questionnaire replaced with “dyesthesia”.

PLOS ONE | https://doi.org/10.1371/journal.pone.0263831  February 17, 2022 3 / 15
Quantitative sensory testing

We used a reduced version (9 out of 13 parameters) of the standardized quantitative sensory testing (QST) protocol of the German Research Network for Neuropathic Pain (DFNS) [27, 28]. The thermotest (Somedic Horby, Sweden) was used to examine cold detection threshold (CDT), warm detection threshold (WDT), paradoxical heat sensation (PHS), thermal sensory limen (TSL), vibration detection threshold (VDT), dynamic mechanical allodynia (DMA), pinprick hyperalgesia, the short version (2/5) of mechanical pain sensitivity (MPS), and pressure pain threshold (PPT). Patients were examined on the dorsum of the right foot corresponding to the S1 segment except for VDT, which was assessed on the right medial malleolus. We used Equista, a data analysis system that transfers data into standard normal distribution (Z-scores) adjusting for age, sex, and body localization [29].

Nerve conduction studies and intraepidermal nerve fiber density

The NCS included examination of sural nerve bilaterally and the median, peroneal, and tibial nerves unilaterally and we defined polyneuropathy as 2 nerves with 1 abnormal parameters with at least 1 sural nerve being abnormal compared with a laboratory control sample [30–32]. Intraepidermal nerve fiber density (IENFD) was considered abnormal if it was lower than the 5th centile for age- and sex-matched healthy controls [19, 33, 34].

Neuropathy subgroups

Small fiber neuropathy (SFN), mixed fiber neuropathy (MFN) and large fiber neuropathy (LFN) were defined according to Itani et al. [35]. SFN as one of following; abnormal pinprick or thermal sensation (bedside or QST) or abnormal IENFD, LFN as one of following; bedside abnormal vibration sensation or ankle reflexes or MDT or abnormal NCS and MFN if not fulfilling criteria for SFN or LFN [35].

Definition of DPN, painful DPN, and dysesthetic DPN

Patients were asked if they had constant or recurring pain in the feet, and those with no pain were asked if their abnormal sensory symptoms in the feet were unpleasant (dysesthesia). In patients with no pain or dysesthesia, we did not systematically differentiate between positive and negative sensory symptoms and thus did not record whether the patient had positive sensory symptoms that were not unpleasant (paresthesia). The intensity of pain was scored on an 11-point NRS, 0–10, with 0 indicating no pain and 10 worst pain imaginable. The intensity of dysesthesia/unpleasantness was scored on the NRS with 0 indicating no dysesthesia/unpleasantness and 10 worst dysesthesia/unpleasantness imaginable.

Patients with confirmed DPN according to the Toronto consensus criteria were divided into 1. Painful DPN, which included patients with neuropathic pain according to NeuPSIG grading system for neuropathic pain, i.e. patients with pain in both feet, 2. Dysesthetic DPN, which included patients with no pain but with unpleasant abnormal sensations in the feet, and 3. DPN without dysesthesia/pain, which included patients that denied any unpleasant or painful sensations in the feet. Paresthesia was included in this group [22, 36].

Ethics statement

All participants signed an informed written consent prior to the examination and the study was approved by the Regional Research Ethics Committee of Central Denmark Region (file number 1-10-72-130-16).
Statistical analysis

For data analysis, we used the STATA version 14 (StataCorp LLC, TX) and R Core Team (2019) [37, 38]. Data were presented as means with standard deviation or as medians with interquartile range (IQR) and categorical data as numbers with percentages. Group comparisons were done with analysis of variance (ANOVA), Kruskal-Wallis test, or Fisher’s exact test between all 3 DPN groups and when significant, we used student’s t-test, Mann-Whitney U test, or Fisher’s exact test for paired comparisons. For the calculation of bedside spreading of sensory loss and gain, the legs were divided into 5 areas (as shown in Fig 3) and we calculated the percentages of patients with abnormalities in each area and depicted the results in the figure. To provide a sum score of bedside sensory loss for each patient, we counted the number of areas with abnormalities. There was no significant difference between sum scores on the right and left leg, confirming symmetrical pattern of sensory loss. We then used Spearman’s rank order correlation to estimate the strength and direction of the association between the sum scores of bedside sensory loss and DPN without dysesthesia/pain, dysesthetic (but non-painful) DPN, and painful DPN assuming a monotonic relationship. We used logistic regressions to estimate odds ratios for having symptoms of anxiety, depression and fatigue (yes/no) for each of the three neuropathy phenotypes.

Results

The study population consisted of 126 patients with confirmed DPN (Fig 1). Of those, 52 (41.3%) had DPN without dysesthesia or pain, 21 (16.7%) had dysesthetic DPN, and 53 (42.1%) had painful DPN. Patients found it easy to separate pain and non-painful dysesthesia (unpleasantness).

There were no differences between the three groups of patients in terms of sex, age, BMI, time since diabetes diagnosis, educational level, and occupational status (Table 1). Fewer patients with painful DPN reported physical activity ≥ 3 times per week than those with no dysesthesia/pain and dysesthesia. Patients with painful DPN reported more pain in other body sites than the feet/legs than DPN patients without dysesthesia/pain. They also used more analgesics, including both drugs normally prescribed for neuropathic pain (TCAs, gabapentin, pregabalin, and SNRIs) and non-prescription drugs (paracetamol and NSAIDs) compared to DPN patients without dysesthesia/pain (Table 1).

There was no difference between the groups regarding the proportion of patients with abnormal NCS, whereas almost all patients with dysesthetic or painful DPN had abnormal IENFD values (Table 1).

Patients with dysesthesia and patients with pain had higher scores for depressive symptoms and a higher proportion had abnormal depression scores compared with patients with DPN
Table 1. Characteristics of patients with confirmed DPN without dysesthesia/pain, dyesthetic DPN and painful DPN.

|                              | DPN without dyesthesia/pain | Dyesthetic DPN | Painful DPN | P     |
|------------------------------|-----------------------------|----------------|-------------|-------|
| **N = 126 (100%), in row**   | 52 (41.3)                   | 21 (16.7)      | 53 (42.1)   |       |
| **Demographics**             |                             |                |             |       |
| Sex, female, n (%)           | 14 (26.9)                   | 6 (28.6)       | 21 (39.6)   | 0.39  |
| Age, years, median (IQR)     | 70.4 (62.0; 73.0)           | 62.2 (52.4; 71.6)| 66.3 (57.5; 70.2) | 0.078 |
| BMI (kg/m^2), median (IQR)   | 31.4 (28.7; 35.6)           | 35.1 (28.9; 38.8) | 34.0 (29.5; 38.5) | 0.095 |
| Time since diabetes diagnosis, years, median (IQR) | 6.1 (4.4;7.1) | 6.4 (3.5; 7.1) | 6.1 (4.7; 7.7) | 0.75  |
| Alcohol consumptions > 7/14 units per week, female/male, n (%) | 4 (7.7) | 3 (14.3) | 7 (13.2) | 0.60  |
| Current smoker, n (%)        | 7 (13.5)                    | 5 (23.8)       | 5 (9.6)     | 0.30  |
| Physical activity ≥ 3 times per week, n (%) | 21 (42.9) | 9 (47.4) | 11 (21.2) | 0.028 |
| Other pain than pain in the feet^, n (%) | 25 (48.1) | 13 (61.9) | 41 (77.4) | 0.008 |
| Educational level (high)^, n (%) | 17 (32.7) | 6 (28.57) | 13 (24.53) | 0.65  |
| Employed, n (%)              | 8 (15.4)                    | 6 (28.6)       | 9 (17.0)    | 0.38  |
| **Analgesics**               |                             |                |             |       |
| Paracetamol and NSAIDs, n (%) | 11 (21.2) | 8 (38.1) | 28 (52.8) | 0.003 |
| TCAs, gabapentin, pregabalin, and SNRIs, n (%) | 1 (1.9) | 2 (9.5) | 16 (30.2) | <0.001 |
| Opioids, n (%)               | 4 (7.7)                     | 4 (19.1)       | 11 (20.8)   | 0.14  |
| **Blood samples**            |                             |                |             |       |
| HbA1C (mmol/mol), median (IQR) | 50.0 (46.0; 55.0) | 47.0 (42.5; 57.0) | 51.0 (45.5; 61.5) | 0.29  |
| Total cholesterol (mmol/L), median (IQR) | 3.9 (3.6; 4.4) | 4.4 (3.6; 5.8) | 3.9 (3.2; 4.5) | 0.070 |
| Triglycerides (mmol/L), median (IQR) | 1.8 (1.5; 2.9) | 2.1 (1.7; 3.2) | 2.0 (1.5; 2.9) | 0.53  |
| **Neuropathy characteristics** |                             |                |             |       |
| NCS abnormal, n (%)          | 34 (66.7)                   | 12 (57.1)      | 35 (66.0)   | 0.13  |
| IENFD abnormal, n (%)        | 33 (70.2)                   | 20 (95.2)      | 42 (91.3)   | 0.01^† |
| Number of IENFD, median (IQR) | 2.6 (1.7;4.1) | 1.6 (0.7;3.0) | 1.2 (0.4;2.7) | 0.002^† |
| SFN, n (%)                   | 1 (1.9)                     | 3 (14.3)       | 2 (3.8)     | 0.11  |
| LFN, n (%)                   | 6 (11.5)                    | 0 (0)          | 1 (1.9)     | 0.064 |
| MFN, n (%)                   | 45 (86.5)                   | 18 (85.7)      | 50 (94.3)   | 0.31  |
| **Mental health**            |                             |                |             |       |
| Quality of life, (NRS 0–10), median (IQR) | 8.0 (7.0;9.0) | 8.0 (7.0;9.0) | 7.0 (5.0;9.0) | 0.13  |
| **PROMIS, T scores, means (SD)** |                     |                |             |       |
| Sleep                        | 49.6 (5.8)                  | 52.1 (4.4)     | 51.2 (4.8)  | 0.12  |
| Anxiety                      | 49.0 (7.1)                  | 52.6 (6.7)     | 50.4 (8.8)  | 0.21  |
| Depression                   | 44.7 (7.2)                  | 51.5 (8.4)     | 49.0 (9.5)  | 0.004^† |
| Fatigue                      | 50.4 (8.6)                  | 56.1 (8.6)     | 56.1 (9.3)  | 0.002^† |
| **PROMIS, number (%) with mild, moderate, and severe symptoms** |                   |                |             |       |
| Sleep                        | 7 (13.5)                    | 5 (23.8)       | 10 (19.2)   | 0.50  |
| Anxiety                      | 10 (19.6)                   | 9 (42.9)       | 17 (32.1)   | 0.11  |
| Depression                   | 5 (9.8)                     | 8 (38.1)       | 15 (28.9)   | 0.010^† |
| Fatigue                      | 21 (40.4)                   | 11 (52.4)      | 29 (54.7)   | 0.32  |
| **PROMIS, Odds ratio (95% confidence intervals) for having mild, moderate or severe symptoms:** |                   |                |             |       |
| Sleep                        | 1                           | 2.0 (0.5;7.2)  | 1.5 (0.5;4.4) |       |
| Anxiety                      | 1                           | 3.1 (1.0;9.3)  | 1.9 (0.8;4.8) |       |
| Depression                   | 1                           | 5.7 (1.6;20.3) | 3.7 (1.2;11.1) |       |

(Continued)
without dysesthesia/pain. Patients with dysesthesia and pain also had higher fatigue scores than patients without dysesthesia/pain, although there was no difference in the percentages with mild, moderate, or severe interference (Table 1).

Most patients had experienced dysesthesia or pain for 1–5 years and around 40% for more than 5 years as compared to the median time from diabetes diagnosis of around 6 years. The average intensity of pain was higher than the average intensity of dysesthesia (Table 2). Pain interfered more often with activities of daily life than dysesthesia (68% vs 38% with mild to severe interference, $P = 0.005$).

### Table 2. Duration, intensity, and interference with daily life of pain and dysesthesia.

|                          | Dysesthetic DPN ($n = 21$) | Painful DPN ($n = 53$) | $P$   |
|--------------------------|-----------------------------|------------------------|-------|
| Duration of sensory symptoms in the feet/legs, n (%) |                          |                        |       |
| Equal to or less 1 year   | 1 (4.8)                     | 7 (13.2)               | 0.43  |
| More than 1 and up to 5 years | 12 (57.1)               | 24 (45.3)              | 0.44  |
| More than 5 years         | 8 (38.1)                    | 22 (41.5)              | 1.00  |
| Pain/dysesthesia spread from the feet to legs, n (%) | 5 (23.8)                   | 24 (45.3)              | 0.12  |
| Pain/dysesthesia in the hands/arms, n (%) | 4 (20.0)                   | 19 (35.9)              | 0.26  |
| Intensity of pain/dysesthesia the last 24 h, NRS (0–10), mean (SD) | 3.5 (2.2)                  | 4.7 (2.8)              | 0.093 |
| Intensity of pain/dysesthesia the last 7 days, NRS (0–10), mean (SD) | 3.8 (1.9)                  | 5.2 (2.4)              | 0.022 |
| PROMIS interference with daily life, T-scores, mean (SD) | 52.1 (7.5)                 | 56.6 (9.2)             | 0.050 |
| PROMIS interference with daily life (mild, moderate, and severe), n (%) | 8 (38.1)                   | 36 (67.9)              | 0.034 |
| Mild                     | 5 (23.8)                    | 16 (30.2)              | -     |
| Moderate                 | 3 (14.3)                    | 18 (34.0)              | -     |
| Severe                   | 0 (0.0)                     | 2 (3.8)                | -     |

PROMIS, Patient Reported Outcome Measures. NRS, Numeric Rating Scale.
The groups reported a similar frequency and intensity of symptoms on the NPSI, except for stabbing and pins and needles sensations where patients with painful DPN reported higher intensity compared to dysesthetic DPN (Table 3).

The QST data are summarized in Fig 2 and Table 4 and S1 Fig. The Z-scores for thermal parameters (WDT and TSL) and mechanical parameters (MDT and MPS) were lower in patients with painful DPN than in patients with DPN without dysesthesia/pain, indicating a greater sensory loss of both small and large nerve fiber function in those with painful DPN with a gradient in increased sensory loss from no dysesthesia/pain to dysesthetic and then painful DPN, except for vibration threshold where patients with dysesthetic DPN had lower

| Symptom description (NPSI) | Dysesthetic DPN (21) | Painful DPN (53) | P       |
|---------------------------|----------------------|-----------------|---------|
|                           | n (%)                | 'NRS 1–10, mean (SD) | n (%)    | 'NRS 1–10, mean (SD) | n (%)/mean (SD) |
| Burning                   | 11 (52.4)            | 4.3 (1.8)       | 34 (64.2) | 5.0 (2.7)         | 0.43/0.39       |
| Squeezing                | 11 (52.4)            | 4.5 (1.9)       | 25 (47.2) | 5.3 (2.9)         | 0.80/0.36       |
| Pressure                  | 10 (47.6)            | 4.2 (1.6)       | 31 (58.5) | 4.7 (2.7)         | 0.44/0.57       |
| Electric shocks           | 7 (33.3)             | 3.1 (2.7)       | 20 (37.7) | 4.8 (2.8)         | 0.79/0.19       |
| Stabbing                 | 14 (66.7)            | 3.6 (2.5)       | 44 (83.0) | 5.7 (2.7)         | 0.21/0.014      |
| Touch-evoked             | 7 (33.3)             | 4.0 (2.1)       | 28 (52.8) | 5.5 (2.6)         | 0.20/0.17       |
| Pressure-evoked          | 5 (23.8)             | 3.4 (1.9)       | 32 (60.4) | 4.8 (2.5)         | 0.009/0.24      |
| Cold-evoked              | 9 (42.9)             | 3.0 (1.8)       | 16 (30.2) | 4.4 (2.8)         | 0.41/0.20       |
| Pins and needles         | 12 (57.1)            | 4.0 (2.1)       | 38 (71.7) | 6.3 (2.2)         | 0.28/0.003      |
| Tingling                 | 13 (61.9)            | 4.1 (2.4)       | 36 (67.9) | 5.3 (2.9)         | 0.79/0.19       |
| Sum score (0–100), mean (SD)** | 18.3 (16.6) | 30.2 (21.1) | 0.023   |

*The NRS (1–10), mean scores are only calculated for those that reported having any of the listed symptoms (more than 0 intensity).

* Mean sum score of all pain/dysesthesia intensities (inclusive those with 0 on the NRS scale).

https://doi.org/10.1371/journal.pone.0263831.t003

Fig 2. Median of QST Z-scores in DPN without dysesthesia/pain, dysesthetic DPN, and painful DPN. WTD, warm detection threshold; CDT, cold detection threshold; TSL, thermal sensory limen; MDT, mechanical detection threshold; VDT, vibration detection threshold; MPS, mechanical pain sensitivity; PPT, pressure pain threshold. P < 0.05 is notified by: * pain vs no dysesthesia/pain, ** dysesthesia vs no dysesthesia/pain, *** pain vs dysesthesia.

https://doi.org/10.1371/journal.pone.0263831.g002
thresholds compared with the other 2 groups (Fig 2). The QST results showed that only few patients had DMA (8% of patients without dysesthesia/pain and 10% of patients with pain) or increased MPS (2% of patients without dysesthesia/pain and 4% of patients with dysesthesia) (S1 Fig).

The bedside examination of the lower extremities displayed a length-dependent distribution of sensory loss from the toes to thighs, with an increasing distribution from DPN without dysesthesia/pain to dysesthetic DPN and painful DPN. There was a positive correlation between going from no dysesthesia/pain to dysesthetic DPN and to painful DPN and the increasing number of areas with decreased sensation of pinprick (VF 5.88) (r_s = 0.35, P < 0.001), brush (r_s = 0.25, P = 0.004) and warmth (40 °C) (r_s = 0.25, P = 0.004). There was also a positive correlation between the number of areas with hyperesthesia and going from no dysesthesia/pain to painful DPN, but in general weak (Fig 3).

In age and sex matched controls without diabetes, none had hypoesthesia to pinprick and light touch (brush) but a few (8, 2%) had hyperesthesia and 15, 5% had cold and 23, 7% warm hypoesthesia (Fig 3).

### Discussion

In this study, we provided a detailed description of patients with dysesthetic and painful DPN in a group of type 2 diabetes patients with relatively newly diagnosed diabetes. Of the 126 patients with confirmed DPN, 51 had no pain or dysesthesia, 21 had dysesthetic DPN, and 53 had painful DPN. We demonstrated that patients with painful DPN had the largest loss of both small and large sensory fiber function in a symmetric, length-dependent distribution and had a larger distribution of sensory abnormalities. There was also a gradient of increasing sensory loss from DPN without dysesthesia/pain to dysesthetic DPN and to painful DPN. The present findings suggest that dysesthesia is present in an intermediate group with less severe neuropathy than those with pain, supporting our hypothesis.

Recently conducted studies with similar definitions of DPN and painful DPN found younger age and higher levels of HbA1c [7], and higher proportion of females and signs of nephropathy [6, 39] in patients with moderate/severe painful DPN compared to patients without pain.
Fig 3. Sensory mapping of lower extremities in controls without diabetes, patients with DPN without dysesthesia/pain, patients with dyesthetic DPN and patients with painful DPN. The correlation between the sum of areas with sensory loss and going from no dysesthesia/pain to dyesthetic DPN and painful DPN. For pinprick: Hypoesthesia: \( r_s = 0.35, P < 0.001 \), Hyperesthesia: \( r_s = 0.13, P = 0.16 \), brush: Hypoesthesia: \( r_s = 0.25, P = 0.004 \), Hyperesthesia: \( r_s = 0.16, P = 0.08 \), warm: Hypoesthesia: \( r_s = 0.25, P = 0.004 \), Hyperesthesia: \( r_s = 0.14, P = 0.12 \) and cold: Hypoesthesia: \( r_s = 0.17, P = 0.06 \), Hyperesthesia: \( r_s = 0.14, P = 0.12 \). Sensory loss or gain is displayed in percentages from the toes to thighs with hypoesthesia to the left and hyperesthesia to the right. We calculated averages (sum scores) for the right and the left side. There was no difference between sum scores on the left and right leg.

https://doi.org/10.1371/journal.pone.0263831.g003
We found a similar tendency for females but not age and HbA1c. Small sample size, shorter duration of diabetes, and type of diabetes could explain some of the discrepancy.

In concert with other studies, we found that patients with painful DPN had more symptoms of depression than patients without pain [7, 40–42]. Patients with dysesthesia also had more symptoms of depression than those with no dysesthesia/pain. In addition, even though they reported less impact on daily life than patients with pain, 38% (24% mild and 14% moderate) reported that dysesthesia had an impact on their daily life, suggesting that dysesthesia, although not labeled as painful by the patients, may be as distressful as pain.

We found that patients with painful DPN were less physically active compared to patients with DPN without dysesthesia/pain and DPN with dysesthesia. A questionnaire study of patients with longstanding type 1 diabetes found that patients who were more physically active reported less neuropathic pain [43]. This could potentially mean that physical activity is protective against pain or that pain reduces physical activity due to pain-related interference with daily life, more depressive symptoms and fatigue.

Only 30% of the patients with painful DPN used medication normally recommended as a first-line therapy for neuropathic pain [44], which is fewer than reported in studies with patients of longer diabetes duration [6, 7, 45] but similar to a study of type 1 and 2 diabetes patients where 37% were treated with at least one of the drugs recommended for neuropathic pain also with longer duration of diabetes [42]. Only 9.5% of patients with dysesthesia received such drugs. It is not known if they requested treatment of their dysesthesia and neuropathic pain drugs have not been tested for dysesthesia despite the impact of dysesthesia. Interestingly, the use of paracetamol and NSAIDs was higher in the pain and dysesthesia groups compared to patients with no pain or dysesthesia. We do not know if that is explained by the fact that they more often had other types of pain or that they are not offered medications recommended for neuropathic pain or if they have stopped using it due to an inadequate effect or side effects [44, 46].

We do not know if dysesthesia presents an intermediate step before development of pain as it is a cross-sectional study and we cannot determine underlying mechanisms from this study. A previous study of patients with neuropathic pain suggested that touch-evoked dysesthesia and pain are transmitted through the same fibers and that the evoked sensation depends on the number of mechanoreceptive fibers that have access to the nociceptive system [47]. Presumably the quality of the symptoms depends to some degree on the type of nerve fiber generating discharges. Based in part on studies from Ochoa and Torebjork using microneurography and ischemic block of nerves in humans it has been suggested that non-painful tingling, prickling and pressing sensations arise from sensory units belonging to large Aβ-fibres, while dull or burning types of pain are generated in C-nociceptive axons [48, 49]. However, it is still discussed how stimuli are encoded to produce the sensation of pain, which may depend on the recruitment of a sufficient number of neurons, activation of specialized high-threshold neurons, or the distribution of activity and interaction across different pathways [50].

The main strength of this study is that the study group consisted of patients diagnosed with confirmed DPN according to widely used standards and patients were recruited from a large patient cohort recruited from both general practitioners and diabetes clinics representative of Danish type 2 diabetes patients with relatively short duration of diabetes [20, 21]. The fact that the clinical examination was carried out at 2 centers could represent a bias, yet we trained the procedures together and checked for consistency regularly throughout the inclusion period. As this was a cross-sectional study, we do not have information on whether patients switch between dysesthesia and pain but this would be important to study in a prospective study. Another limitation is that we did not assess the presence of paresthesia.

In conclusion, there was a gradient in the distribution of sensory loss from DPN without dysesthesia/pain to dysesthesia and then painful DPN, where patients with painful DPN
presented with most severe neuropathy. Patients with painful DPN reported less physical activity and patients with pain and dysesthesia had more symptoms of depression than patients with DPN and no pain. The group of patients with dysesthesia resembled patients with pain regarding clinical and demographic data and described their dysesthetic symptoms similar to those with pain according to the NPSI.

Supporting information

S1 Fig. Quantitative sensory testing. Percentages of patients with loss (-%) and gain (+%) of sensory functions in DPN without dysesthesia/pain, dysesthetic DPN, and painful DPN. WTD, warm detection threshold; CDT, cold detection threshold; TSL, thermal sensory limen; MDT, mechanical detection threshold; VDT, vibration detection threshold; DMA, dynamic mechanical allodynia; PHS, paradoxical heat sensation; MPS, mechanical pain sensitivity; PPT, pressure pain threshold. \( P < 0.05 \) is notified by: "pain vs no dysesthesia/pain, **dysesthesia vs no dysesthesia/pain, ***pain vs dysesthesia. (TIF)

Acknowledgments

The authors thank all patients for their participation in the study, Helle O. Andersen for secretarial and language revision and research nurses Rud Bugge Andersen, Bente Christensen, Tine Birkeholm Leth, and Elma Budalica for their help with the data collection.

Author Contributions

Conceptualization: Sandra Sif Gylfadottir, Mustapha Itani, Alexander Gramm Kristensen, Pall Karlsson, Thomas Kroigård, David L. Bennett, Hatice Tankisi, Niels Trolle Andersen, Troels Staehelin Jensen, Søren Hein Sindrup, Nanna Brix Finnerup.

Formal analysis: Sandra Sif Gylfadottir, Alexander Gramm Kristensen, Niels Trolle Andersen.

Funding acquisition: Troels Staehelin Jensen.

Investigation: Sandra Sif Gylfadottir, Mustapha Itani, Alexander Gramm Kristensen, Pall Karlsson, Thomas Kroigård.

Methodology: Sandra Sif Gylfadottir, Mustapha Itani, Alexander Gramm Kristensen, Pall Karlsson, Thomas Kroigård, David L. Bennett, Hatice Tankisi, Niels Trolle Andersen, Troels Staehelin Jensen, Søren Hein Sindrup, Nanna Brix Finnerup.

Project administration: Sandra Sif Gylfadottir, Mustapha Itani, Hatice Tankisi, Troels Staehelin Jensen, Søren Hein Sindrup, Nanna Brix Finnerup.

Resources: Sandra Sif Gylfadottir, Mustapha Itani, Alexander Gramm Kristensen, Pall Karlsson, Thomas Kroigård.

Supervision: Pall Karlsson, Hatice Tankisi, Nanna Brix Finnerup.

Visualization: Sandra Sif Gylfadottir.

Writing – original draft: Sandra Sif Gylfadottir.

Writing – review & editing: Sandra Sif Gylfadottir, Mustapha Itani, Alexander Gramm Kristensen, Pall Karlsson, Thomas Kroigård, David L. Bennett, Hatice Tankisi, Niels Trolle Andersen, Troels Staehelin Jensen, Søren Hein Sindrup, Nanna Brix Finnerup.
References

1. Feldman EL, Nave KA, Jensen TS, Bennett DL. New Horizons in Diabetic Neuropathy: Mechanisms, Bioenergetics, and Pain. Neurom 2017; 93(6):1296–313. Epub 2017/03/24. https://doi.org/10.1016/j.neuro.2017.02.005 PMID: 28334605; PubMed Central PMCID: PMC5400015.

2. Shillo P, Sloan G, Greig M, Hunt L, Selvarajah D, Elliott J, et al. Painful and Painless Diabetic Neuropathies: What Is the Difference? Current diabetes reports. 2019; 19(6):32. Epub 2019/05/09. https://doi.org/10.1007/s11892-019-1150-5 PMID: 31065863; PubMed Central PMCID: PMC6505492.

3. Feldman EL, Callaghan BC, Pop-Busui R, Zochodne DW, Wright DE, Bennett DL, et al. Diabetic neuropathy. Nature reviews Disease primers. 2019; 5(1):41. Epub 2019/06/15. https://doi.org/10.1038/s41572-019-0092-1 PMID: 31197153.

4. Yach D, Stuckler D, Brownell KD. Epidemiologic and economic consequences of the global epidemics of obesity and diabetes. Nature medicine. 2006; 12(1):62–6. Epub 2006/01/07. https://doi.org/10.1038/nm0106-62 PMID: 16397571.

5. Hebert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. Pain. 2016. Epub 2016/12/13. https://doi.org/10.1097/j.pain.0000000000000491 PMID: 27941499.

6. Raputova J, Srotova I, Vickova E, Sommer C, Uceyler N, Birklein F, et al. Sensory phenotype and risk factors for painful diabetic neuropathy: a cross-sectional observational study. Pain. 2017; 158 (12):2340–53. Epub 2017/09/01. https://doi.org/10.1097/j.pain.00000000001034 PMID: 28958986; PubMed Central PMCID: PMC6509294.

7. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. Pain. 2016; 157(5):1132–45. Epub 2016/04/19. https://doi.org/10.1097/j.pain.000000000000491 PMID: 27088890.

8. Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful and painless diabetic neuropathy. Pain. 2016; 157(5):1132–45. Epub 2016/04/19. https://doi.org/10.1097/j.pain.000000000000491 PMID: 27088890.

9. Raja SN, Carr DB, Cohen M, Finnerup NB, Flor H, Gibson S, et al. The revised International Association for the Study of Pain definition of pain: concepts, challenges, and compromises. Pain. 2020. Epub 2020/07/23. https://doi.org/10.1097/j.pain.000000000001939 PMID: 32694387; PubMed Central PMCID: PMC7680716.

10. Bogduk HMaN. IASP taxonomy 1994 [cited 2020 01.03.2020]. Available from: https://www.iasp-pain.org/terminology?navItemNumber=576).

11. Berić A, Dimitrijević MR, Lindblom U. Central dysesthesia syndrome in spinal cord injury patients. Pain. 1998; 34(2):109–16. Epub 1998/07/01. https://doi.org/10.1016/0304-3959(88)90155-8 PMID: 3588000.

12. Davidoff G, Roth E, Guaracini M, Sliva J, Yarkony G. Function-limiting dysesthetic pain syndrome among traumatic spinal cord injury patients: a cross-sectional study. Pain. 1987; 29(1):39–48. Epub 1987/04/01. https://doi.org/10.1016/0304-3959(87)90176-X PMID: 3588000.

13. Andersen G, Vestergaard K, Ingeman-Nielsen M, Jensen TS. Incidence of central post-stroke pain. Pain. 1995; 61(2):187–93. Epub 1995/05/01. https://doi.org/10.1016/0304-3959(94)00144-4 PMID: 7659428.

14. Klit H, Finnerup NB, Andersen G, Jensen TS. Central poststroke pain: a population-based study. Pain. 2011; 152(4):818–24. Epub 2011/01/29. https://doi.org/10.1016/j.pain.2010.12.030 PMID: 21272999.

15. Finnerup NB, Johannesen IL, Fuglsang-Frederiksen A, Bach FW, Jensen TS. Sensory function in spinal cord injury patients with and without central pain. Brain: a journal of neurology. 2003; 126(1 Pt 1):57–70. Epub 2002/12/13. https://doi.org/10.1093/brain/awg007 PMID: 12477697.

16. Störmøyer S, Gerner HJ, Grüninger W, Metzmacber K, Föllinger S, Wienke C, et al. Chronic pain/dysesthesia in spinal cord injury patients: results of a multicentre study. Spinal cord. 1997; 35(7):446–55. Epub 1997/07/01. https://doi.org/10.1038/sj.sc.3100441 PMID: 9232750.

17. Finnerup NB, Norrbright C, Trok K, Pielh F, Johannesen IL, Sørensen JC, et al. Phenotypes and predictors of pain following traumatic spinal cord injury: a prospective study. The journal of pain: official journal of the American Pain Society. 2014; 15(1):40–8. Epub 2013/11/26. https://doi.org/10.1016/j.jpain.2013.09.008 PMID: 24268112.

18. Klit H, Hansen AP, Marcussen NS, Finnerup NB, Jensen TS. Early evoked pain or dysesthesia is a predictor of central poststroke pain. Pain. 2014; 155(12):2699–706. Epub 2014/10/07. https://doi.org/10.1016/j.pain.2014.09.037 PMID: 25284071.

19. Gyldfadottir SS, Itàni M, Krigård T, Kristensen AG, Christensen DH, Nicolaisen SK, et al. Diagnosis and prevalence of diabetic polyneuropathy: a cross-sectional study of Danish patients with type 2 diabetes.
European journal of neurology. 2020; 27(12):2575–85. Epub 2020/09/11. https://doi.org/10.1111/ene.01446 PMID: 32909392.

20. Gyldfodd SS, Christensen DH, Nicolaisen SK, Andersen H, Callaghan BC, Itani M, et al. Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. Pain. 2020; 161(3):574–83. Epub 2019/11/07. https://doi.org/10.1097/j.pain.0000000000001744 PMID: 31693539; PubMed Central PMCID: PMC7017941.

21. Christensen DH, Nicolaisen SK, Berencsi K, Beck-Nielsen H, Runbjerg J, Friborg S, and the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) project cohort of newly diagnosed patients with type 2 diabetes: a cohort profile. BMJ open. 2018; 8(4):e017273. Epub 2018/04/09. https://doi.org/10.1136/bmjopen-2017-017273 PMID: 29627803; PubMed Central PMCID: PMC5882767.

22. Tesfaye S, Boulton AJ, Dyck PJ, Freeman R, Horowitz M, Kempker P, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes care. 2010; 33(10):2285–93. Epub 2010/09/30. https://doi.org/10.2337/dc10-1303 PMID: 20876709; PubMed Central PMCID: PMC2945176.

23. Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. Jama. 1994; 272(8):619–26. Epub 1994/08/24. PMID: 7726894.

24. Pilkonis PA, Choi SW, Reise SP, Stover AM, Riley WT, Cella D. Item banks for measuring emotional distress from the Patient-Reported Outcomes Measurement Information System (PROMIS(R)): depression, anxiety, and anger. Assessment. 2011; 19(3):263–83. Epub 2011/06/24. https://doi.org/10.1177/1073191111411467 PMID: 21697139; PubMed Central PMCID: PMC3153635.

25. HealthMeasureS. PROMIS health measures [2018/03/22]. Available from: http://www.healthmeasures.net/score-and-interpret/interpret-scores/promis.

26. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004; 108(3):248–57. Epub 2004/03/20. https://doi.org/10.1016/j.j.pain.2003.12.024 PMID: 1503944.

27. Rolke R, Baron R, Maier C, Tolle TR, Treede RD, Beyer A, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006; 123(3):231–43. Epub 2006/05/16. https://doi.org/10.1016/j.pain.2006.01.041 PMID: 16697110.

28. Rolke R, Magele W, Campbell KA, Schalber C, Caspari S, Birklein F, et al. Quantitative sensory testing: a comprehensive protocol for clinical trials. European journal of pain (London, England). 2006; 10 (1):77–88. Epub 2005/11/18. https://doi.org/10.1016/j.jepain.2005.02.003 PMID: 16291301.

29. Magele W, Krumova EH, Baron R, Tolle T, Treede RD, Maier C. Reference data for quantitative sensory testing (QST): refined stratification for age and a novel method for statistical comparison of group data. Pain. 2010; 151(3):598–605. Epub 2010/10/23. https://doi.org/10.1016/j.j.pain.2010.07.026 PMID: 20966568.

30. Stalberg E, van Dijk H, Falck B, Kimura J, Neuwirth C, Pitt M, et al. Standards for quantification of EMG and neurography. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2019; 130(9):1688–729. Epub 2019/06/20. https://doi.org/10.1016/j.clinph.2019.05.008 PMID: 31213353.

31. Tankisi H, Pugdahl K, Fuglsang Frederiksen A, Johnsen B, de Carvalho M, Fawcett PR, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clinical neurophysiology: official journal of the International Federation of Clinical Neurophysiology. 2005; 116(7):1571–80. Epub 2005/05/24. https://doi.org/10.1016/j.clinph.2005.04.003 PMID: 15907395.

32. Dyck PJ, Albers JW, Andersen H, Arezzo JC, Biessels GJ, Brill V, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes/metabolism research and reviews. 2011; 27(7):620–8. Epub 2011/06/23. https://doi.org/10.1002/dmrr.1226 PMID: 21695763.

33. Costa YM, Karlsson P, Bonjardim LR, Conti CR, Tankisi H, Jensen TS, et al. Trigeminal nociceptive function and oral somatosensory functional and structural assessment in patients with diabetic peripheral neuropathy, Scientific reports. 2019; 9(1):169. Epub 2019/01/19. https://doi.org/10.1038/s41598-018-37041-4 PMID: 30655584; PubMed Central PMCID: PMC6336810.

34. Lauria G, Hsieh ST, Johansson O, Kennedy WR, Leger JM, Mellgren SI, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European journal of neurology. 2010; 17(7):903–12, e44-8. Epub 2010/07/21. https://doi.org/10.1111/j.1468-1331.2010.03023.x PMID: 20642627.
35. Itani M, Gyldadottir SS, Krøågård T, Kristensen AG, Christensen DH, Karlsson P, et al. Small and large fiber sensory polyneuropathy in type 2 diabetes: Influence of diagnostic criteria on neuropathy subtypes. Journal of the peripheral nervous system: JPNS. 2021; 26(1):55–65. Epub 2020/12/10. https://doi.org/10.1111/jns.12424 PMID: 33295647.

36. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016. Epub 2016/04/27. https://doi.org/10.1097/j.pain.0000000000000492 PMID: 27115670.

37. Team RC. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019.

38. HW. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York. 2016.

39. Truini A, Spallone V, Morganti R, Tamburin S, Zanette G, Schenone A, et al. A Cross Sectional Study Investigating Frequency and Features of Definitely Diagnosed Diabetic Painful Polyneuropathy. Pain. 2018. Epub 2018/08/31. https://doi.org/10.1097/j.pain.000000000001378 PMID: 30161042.

40. D'Amato C, Morganti R, Greco C, Di Gennaro F, Cacciotti L, Longo S, et al. Diabetic peripheral neuropathic pain is a stronger predictor of depression than other diabetic complications and comorbidities. Diabetes & vascular disease research. 2016; 13(6):418–28. Epub 2016/06/24. https://doi.org/10.1016/j.dvdr.2016.06.008 PMID: 27334483.

41. Vileikyte L, Peyrot M, Gonzalez JS, Rubin RR, Garrow AP, Stickings D, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009; 52(7):1265–73. Epub 2009/04/29. https://doi.org/10.1007/s00125-009-1363-2 PMID: 19399473.

42. Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PloS one. 2013; 8(9):e74195. Epub 2013/09/24. https://doi.org/10.1371/journal.pone.0074195 PMID: 24058527; PubMed Central PMCID: PMC3772849.

43. Cardinez N, Lovblom LE, Bai JW, Lewis E, Abraham A, Scarr D, et al. Sex differences in neuropathic pain in longstanding diabetes: Results from the Canadian Study of Longevity in Type 1 Diabetes. Journal of diabetes and its complications. 2018; 32(7):660–4. Epub 2018/06/23. https://doi.org/10.1016/j.jdiacomp.2018.05.001 PMID: 29929836.

44. Finnerup NB, Attal N, Haroutounian S, McNicoll E, Baron R, Dworkin RH, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. The Lancet Neurology. 2015; 14(2):162–73. Epub 2015/01/13. https://doi.org/10.1016/S1474-4422(14)70251-0 PMID: 25575710; PubMed Central PMCID: PMC4493167.

45. Gore M, Brandenburg NA, Hoffman DL, Tai KS, Stacey B. Burden of illness in painful diabetic peripheral neuropathy: the patients’ perspectives. The journal of pain: official journal of the American Pain Society. 2006; 7(12):892–900. Epub 2006/12/13. https://doi.org/10.1016/j.jpain.2006.04.013 PMID: 17157775.

46. Giannopoulos S, Pelidou SH, Kyritsis AP, Kosmidou M. Burden of Illness in Painful Diabetic Peripheral Neuropathy. The journal of pain: official journal of the American Pain Society. 2007; 8(6):530. Epub 2007/05/08. https://doi.org/10.1016/j.jpain.2007.04.001 PMID: 17481958.

47. Landerholm AH, Hansson PT. Mechanisms of dynamic mechanical allodynia and dysesthesia in patients with peripheral and central neuropathic pain. European journal of pain (London, England). 2011; 15(5):498–503. Epub 2010/11/26. https://doi.org/10.1016/j.ejpain.2010.03.003 PMID: 21094619.

48. Ochoa JL, Torebjork HE. Paraesthesiae from ectopic impulse generation in human sensory nerves. Brain: a journal of neuroscience. 1980; 103(4):835–53. Epub 1980/12/01. https://doi.org/10.1093/brain/103.4.835 PMID: 6254609.

49. Mogoryos I, Bostock H, Burke D. Mechanisms of paresthesias arising from healthy axons. Muscle & nerve. 2000; 23(3):310–20. Epub 2000/02/19. https://doi.org/10.1002/(sici)1097-4598(200003)23:3<310::aid-mus2>3.0.co;2-a PMID: 10679707.

50. Prescott SA, Ma Q, De Koninck Y. Normal and abnormal coding of somatosensory stimuli causing pain. Nature neuroscience. 2014; 17(2):183–91. Epub 2014/01/30. https://doi.org/10.1038/nn.3629 PMID: 24473266; PubMed Central PMCID: PMC4079041.